476334-31-3

Usage

Uses

Used in Pharmaceutical Industry:
(R)-BoroPhg(+)-Pinanediol-HCl is used as a catalyst for enhancing the enantioselectivity of catalytic reactions, which is crucial for the production of pharmaceuticals with desired chiral properties. (R)-BoroPhg(+)-Pinanediol-HCl's ability to selectively catalyze reactions can lead to the synthesis of enantiomerically pure drugs, improving their efficacy and reducing potential side effects.
Used in Organic Synthesis:
(R)-BoroPhg(+)-Pinanediol-HCl is used as a versatile catalyst in organic synthesis for its capacity to form reversible covalent bonds with a variety of substrates. This feature makes it suitable for a wide range of reactions, contributing to the development of new synthetic pathways and the production of complex organic molecules.
Used in the Synthesis of Complex Natural Products:
(R)-BoroPhg(+)-Pinanediol-HCl is employed as a catalyst in the synthesis of complex natural products, where its enantioselective properties are particularly valuable. (R)-BoroPhg(+)-Pinanediol-HCl aids in the production of natural product analogs and derivatives with specific chiral configurations, which can be important for biological activity and potential therapeutic applications.
Used in the Production of Chiral Building Blocks:
(R)-BoroPhg(+)-Pinanediol-HCl is used as a catalyst for the synthesis of chiral building blocks, which are essential components in the creation of enantiomerically pure compounds. These building blocks are vital for the development of new pharmaceuticals, agrochemicals, and other specialty chemicals that require specific stereochemistry for optimal performance.

Upstream product

• 22422-34-0 (1R,2R,3S,5R)-2,3-pinane diol 

Relevant academic research and scientific papers

Structure-based development of (1-(3′-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- And Serine-β-lactamases

The emergence and spread of bacterial pathogens acquired metallo-β-lactamase (MBL) and serine-β-lactamase (SBL) medicated β-lactam resistance gives rise to an urgent need for the development of new dual-action MBL/SBL inhibitors. Application of a pharmacophore fusion strategy led to the identification of (2′S)-(1-(3′-mercapto-2′-methylpropanamido)methyl)boronic acid (MS01) as a new dual-action inhibitor, which manifests broad-spectrum inhibition to representative MBL/SBL enzymes, including the widespread VIM-2 and KPC-2. Guided by the VIM-2:MS01 and KPC-2:MS01 complex structures, further structural optimization yielded new, more potent dual-action inhibitors. Selectivity studies indicated that the inhibitors had no apparent inhibition to human angiotensin-converting enzyme-2 and showed selectivity across serine hydrolyases in E. coli and human HEK293T cells labeled by the activity-based probe TAMRA-FP. Moreover, the inhibitors displayed potentiation of meropenem efficacy against MBL- or SBL-positive clinical isolates without apparent cytotoxicity. This work will aid efforts to develop new types of clinically useful dual-action inhibitors targeting MBL/SBL enzymes.

Mercapto-amide boronic acid derivative and application thereof as MBL (metal beta-lactamase) and/or SBL (serine beta-lactamase) inhibitor

The invention provides a compound of a formula (I) shown in the specification, or a conformational isomer, or an optical isomer or a pharmaceutically acceptable salt thereof. The compound of the formula (I) shown in the specification has excellent broad-spectrum inhibitory activity on MBL (metal beta-lactamase) and/or SBL (serine beta-lactamase), and can be used for preparing MBL and/or SBL inhibitors. Moreover, the compound disclosed by the invention has excellent antibacterial activity on multiple drug-resistant bacteria and is capable of reversing drug resistance of carbapenem drug-resistant bacteria, and the antibacterial effect of the compound is prior to those of positive control products such as L-captopril and tazobactam. The compound disclosed by the invention has very great potential in preparation of MBL/SBL dual inhibitors and medicines reversing drug resistance of carbapenem drug-resistance bacteria.